Empatica joins CancerX to help in the fight against cancer
We are excited to share that last week, at the American Society of Clinical Oncology Annual Meeting 2023, Empatica was announced as a founding member of CancerX.
CancerX is a public-private partnership (PPP) co-hosted by Moffitt Cancer Center and the Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH).
CancerX was announced in February 2023 as part of The White House’s reignited national Cancer Moonshot initiative.
The vision of CancerX is to act as a national accelerator to boost innovation and design a future that is free from cancer.
Mission and goal
In March 2023, CancerX announced its inaugural project, “Advancing Digital Innovation to Improve Equity and Reduce Financial Toxicity in Cancer Care and Research,” which has begun work to assess and enhance the impact of digital solutions on cancer care cost, access, outcomes, and inclusion.
This initiative brings together a diverse range of innovators, united by a strong commitment to act swiftly, to propel digital solutions, and build a future that is cancer free.
Empatica is proud to be part of the united CancerX founding members, providing our Empatica Health Monitoring Platform and expertise on digital biomarker development to help advance solutions needed in the fight against cancer.
We are delighted to be involved in this project, working with other innovative organizations and partners to help transform the lives of millions.
For more information on CancerX, please visit their website. We look forward to sharing CancerX’s progress with you.